Immunobiology and immunotherapy in genitourinary malignancies.

@article{Tsiatas2016ImmunobiologyAI,
  title={Immunobiology and immunotherapy in genitourinary malignancies.},
  author={M. Tsiatas and P. Grivas},
  journal={Annals of translational medicine},
  year={2016},
  volume={4 14},
  pages={
          270
        }
}
  • M. Tsiatas, P. Grivas
  • Published 2016
  • Medicine
  • Annals of translational medicine
  • Immunotherapy has traditionally been a critical component of the cancer treatment armamentarium in genitourinary (GU) cancers. It has an established role in the management of carefully selected patients with metastatic renal cell carcinoma (RCC) [e.g., high dose interleukin-2 (IL-2)] and non-muscle invasive bladder cancer (NMIBC) [e.g., intravesical Bacillus Calmette-Guérin (BCG)]. In 2010, the sipuleucel-T vaccine was approved by the FDA for the management of metastatic castration-resistant… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    According to the high expression of tumor cell-associated antigen Nectin4 in patients with solid tumors such as non-small cell lung cancer, breast cancer, ovarian cancer, bladder… Expand
    ConditionsNectin4-positive Advanced Malignant Solid Tumor
    InterventionBiological
    Supportive care for patients undergoing immunotherapy
    • 26
    • Highly Influenced
    • PDF
    Immunotherapy in genitourinary cancers: where are we going?
    • 1
    Management and Supportive Care of Patients Undergoing Immunotherapy

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 86 REFERENCES
    Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    • 3,999
    • PDF
    Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
    • 2,987
    • PDF
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    • 8,127
    • PDF
    Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
    • 5,189
    • PDF
    Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
    • 687
    Increased survival with enzalutamide in prostate cancer after chemotherapy.
    • 2,988
    • PDF
    Enzalutamide in metastatic prostate cancer before chemotherapy.
    • 1,668
    • PDF
    Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    • 3,251
    • PDF
    Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    • 1,207
    • PDF